Relmada Therapeutics Inc (RLMD)

$4.85 +0.08 (1.68%)
Market Cap 508.82M
Revenue (ttm) 0.00
Net Income (ttm) -57.39M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 751,600
Avg Vol 1,948,788
Day's Range N/A - N/A
Shares Out 106.67M
Stochastic %K 41%
Beta 0.46
Analysts Strong Sell
Price Target $12.67

Company Profile

Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessiv...

Industry: Biotechnology
Sector: Healthcare
Phone: 786 629 1376
Address:
2222 Ponce de Leon Blvd., Floor 3, Coral Gables, United States
VolcanicTrades
VolcanicTrades Aug. 11 at 11:49 PM
$RLMD lot of bio stocks curling up….$BEAT $ONCO $GLMD
0 · Reply
teaman60
teaman60 Aug. 7 at 11:16 AM
$RLMD I was right
1 · Reply
StocktwitsEarnings
StocktwitsEarnings Aug. 6 at 10:04 PM
$RLMD Q2 '26 Earnings Results & Recap Reported GAAP EPS of -$0.11 up 63.33% YoY
0 · Reply
EarningsInsider
EarningsInsider Aug. 6 at 9:22 PM
https://www.marketbeat.com/earnings/reports/2026-8-6-relmada-therapeutics-inc-stock/ $RLMD Relmada Therapeutics Earnings Transcript
0 · Reply
teaman60
teaman60 Aug. 5 at 1:59 AM
$RLMD Well we have passed the time when they said test results would be released so I am not expecting good news on this.
1 · Reply
Lane0507
Lane0507 Aug. 4 at 10:49 PM
$RLMD A sleeper ready to bounce
0 · Reply
Quantumup
Quantumup Jul. 31 at 12:21 PM
$NBIX Baird-OP⬆️$225 was$186 Stifel-Buy⬆️$215 was$188 SLNO $RYTM $RLMD HRMY Needham-Buy⬆️$204 was$200~continue2see meaningful NBIX upside—driven by an established Ingrezza franchise—2 add'l growth products—well funded pipeline—w/ multiple data readouts '27+ Guggenheim-Buy⬆️$222 was $200; Here's what Guggenheim had to say in its note to investors: https://x.com/Quantumup1/status/2083165891739390434?s=20
0 · Reply
focafoca99
focafoca99 Jul. 28 at 12:47 PM
$RLMD installed Bipin Dalmia, PhD, MBA as its new chief business officer.
1 · Reply
PLATINUM_TRADES
PLATINUM_TRADES Jul. 22 at 1:52 PM
$RLMD $5.11 Is the 200 major support I expect a bounce 🚨🚨
1 · Reply
PLATINUM_TRADES
PLATINUM_TRADES Jul. 22 at 1:40 PM
$RLMD Adds!! No reason for this to be this low imo... $5.50 Possible next🔋🔋
0 · Reply
Latest News on RLMD
Relmada Therapeutics reports Q2 EPS (11c), consensus (20c)

2026-08-06T21:35:46.000Z - 12 days ago

Relmada Therapeutics reports Q2 EPS (11c), consensus (20c)

Relmada Therapeutics Earnings Call Transcript: Q2 2026

Aug 6, 2026, 4:30 PM EDT - 12 days ago

Relmada Therapeutics Earnings Call Transcript: Q2 2026

Relmada Therapeutics Quarterly report: Q2 2026

Aug 6, 2026, 4:30 PM EDT - 12 days ago

Relmada Therapeutics Quarterly report: Q2 2026

Relmada Therapeutics Earnings release: Q2 2026

Aug 6, 2026, 4:30 PM EDT - 12 days ago

Relmada Therapeutics Earnings release: Q2 2026

Relmada Therapeutics appoints Bipin Dalmia as chief business officer

2026-07-28T13:20:34.000Z - 21 days ago

Relmada Therapeutics appoints Bipin Dalmia as chief business officer

Relmada Therapeutics names Bipin Dalmia chief business officer

2026-07-28T13:15:20.000Z - 21 days ago

Relmada Therapeutics names Bipin Dalmia chief business officer

Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia as Chief Business Officer

Jul 28, 2026, 8:30 AM EDT - 22 days ago

Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia as Chief Business Officer

Relmada Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026

Jul 16, 2026, 7:05 AM EDT - 4 weeks ago

Relmada Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026

Relmada Therapeutics joins Russell 2000, Russell 3000 Indexes

2026-06-29T11:10:10.000Z - 7 weeks ago

Relmada Therapeutics joins Russell 2000, Russell 3000 Indexes

Relmada Therapeutics Joins Russell 2000® and Russell 3000® Indexes

Jun 29, 2026, 7:00 AM EDT - 7 weeks ago

Relmada Therapeutics Joins Russell 2000® and Russell 3000® Indexes

Relmada Therapeutics initiated with a Buy at H.C. Wainwright

2026-06-18T10:07:12.000Z - 2 months ago

Relmada Therapeutics initiated with a Buy at H.C. Wainwright

Relmada Therapeutics Appoints CNS Drug Development Veteran Michael Quirk as Senior Advisor for Sepranolone Program

Jun 11, 2026, 7:00 AM EDT - 2 months ago

Relmada Therapeutics Appoints CNS Drug Development Veteran Michael Quirk as Senior Advisor for Sepranolone Program

Relmada Therapeutics Slides: Corporate presentation

Jun 9, 2026, 7:00 AM EDT - 2 months ago

Relmada Therapeutics Slides: Corporate presentation

Relmada Therapeutics Transcript: Jefferies Global Healthcare Conference 2026

Jun 4, 2026, 12:50 PM EDT - 2 months ago

Relmada Therapeutics Transcript: Jefferies Global Healthcare Conference 2026

Relmada Therapeutics to Present at the Jefferies Global Healthcare Conference

May 28, 2026, 7:00 AM EDT - 2 months ago

Relmada Therapeutics to Present at the Jefferies Global Healthcare Conference

Relmada Therapeutics Transcript: AGM 2026

May 27, 2026, 9:30 AM EDT - 2 months ago

Relmada Therapeutics Transcript: AGM 2026

Relmada Therapeutics files automatic mixed securities shelf

2026-05-13T21:24:00.000Z - 3 months ago

Relmada Therapeutics files automatic mixed securities shelf

Relmada Therapeutics Earnings Call Transcript: Q1 2026

May 12, 2026, 4:30 PM EDT - 3 months ago

Relmada Therapeutics Earnings Call Transcript: Q1 2026

Relmada Therapeutics Quarterly report: Q1 2026

May 12, 2026, 4:30 PM EDT - 3 months ago

Relmada Therapeutics Quarterly report: Q1 2026

Relmada Therapeutics Earnings release: Q1 2026

May 12, 2026, 4:30 PM EDT - 3 months ago

Relmada Therapeutics Earnings release: Q1 2026

Relmada Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

May 12, 2026, 4:05 PM EDT - 3 months ago

Relmada Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Relmada Therapeutics Slides: Company presentation

May 12, 2026, 7:00 AM EDT - 3 months ago

Relmada Therapeutics Slides: Company presentation

Relmada Therapeutics Slides: Corporate presentation

May 12, 2026, 7:00 AM EDT - 3 months ago

Relmada Therapeutics Slides: Corporate presentation

Relmada Therapeutics to Report First Quarter 2026 Financial Results on Tuesday, May 12, 2026

May 6, 2026, 7:00 AM EDT - 3 months ago

Relmada Therapeutics to Report First Quarter 2026 Financial Results on Tuesday, May 12, 2026

Relmada Therapeutics to Present NDV-01 Abstracts at AUA2026

May 5, 2026, 7:00 AM EDT - 3 months ago

Relmada Therapeutics to Present NDV-01 Abstracts at AUA2026

Relmada Therapeutics Proxy statement: Proxy filing

Apr 17, 2026, 8:00 AM EDT - 4 months ago

Relmada Therapeutics Proxy statement: Proxy filing

Relmada Therapeutics Proxy statement: Proxy filing

Apr 17, 2026, 8:00 AM EDT - 4 months ago

Relmada Therapeutics Proxy statement: Proxy filing

Relmada Therapeutics Proxy statement: Proxy filing

Apr 6, 2026, 8:00 AM EDT - 4 months ago

Relmada Therapeutics Proxy statement: Proxy filing

Relmada Therapeutics Registration statement: Registration filing

Apr 3, 2026, 8:00 AM EDT - 4 months ago

Relmada Therapeutics Registration statement: Registration filing

Relmada Therapeutics Slides: Corporate presentation

Mar 30, 2026, 7:00 AM EDT - 5 months ago

Relmada Therapeutics Slides: Corporate presentation

Relmada Therapeutics initiated with an Overweight at Piper Sandler

2026-03-24T09:00:12.000Z - 5 months ago

Relmada Therapeutics initiated with an Overweight at Piper Sandler

Relmada Therapeutics price target raised to $19 from $10 at Mizuho

2026-03-20T11:37:53.000Z - 5 months ago

Relmada Therapeutics price target raised to $19 from $10 at Mizuho

Relmada Therapeutics Earnings Call Transcript: Q4 2025

Mar 19, 2026, 4:30 PM EDT - 5 months ago

Relmada Therapeutics Earnings Call Transcript: Q4 2025

Relmada Therapeutics Annual report: Q4 2025

Mar 19, 2026, 4:30 PM EDT - 5 months ago

Relmada Therapeutics Annual report: Q4 2025

Relmada Therapeutics Earnings release: Q4 2025

Mar 19, 2026, 4:30 PM EDT - 5 months ago

Relmada Therapeutics Earnings release: Q4 2025

Relmada Therapeutics Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update

Mar 19, 2026, 4:01 PM EDT - 5 months ago

Relmada Therapeutics Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update

Relmada Therapeutics Slides: Study Result Presentation

Mar 19, 2026, 7:00 AM EDT - 5 months ago

Relmada Therapeutics Slides: Study Result Presentation

Relmada Therapeutics Slides: Corporate presentation

Mar 19, 2026, 7:00 AM EDT - 5 months ago

Relmada Therapeutics Slides: Corporate presentation

Relmada Therapeutics to Report Fourth Quarter 2025 Financial Results on Thursday, March 19, 2026

Mar 12, 2026, 7:00 AM EDT - 5 months ago

Relmada Therapeutics to Report Fourth Quarter 2025 Financial Results on Thursday, March 19, 2026

Relmada Therapeutics Transcript: Leerink Global Healthcare Conference 2026

Mar 10, 2026, 8:40 AM EDT - 5 months ago

Relmada Therapeutics Transcript: Leerink Global Healthcare Conference 2026

Relmada Therapeutics to Present at the Leerink Partners Global Healthcare Conference

Mar 9, 2026, 4:30 PM EDT - 5 months ago

Relmada Therapeutics to Present at the Leerink Partners Global Healthcare Conference

Why Is Relmada Therapeutics Stock (RLMD) Up Today?

2026-03-09T12:00:38.000Z - 5 months ago

Why Is Relmada Therapeutics Stock (RLMD) Up Today?

Relmada Therapeutics prices 29.47M shares at $4.75 in private placement

2026-03-09T11:30:59.000Z - 5 months ago

Relmada Therapeutics prices 29.47M shares at $4.75 in private placement

Relmada Therapeutics reports 12-month Phase 2 interim data for NDV-01

2026-03-09T11:15:52.000Z - 5 months ago

Relmada Therapeutics reports 12-month Phase 2 interim data for NDV-01

Relmada Therapeutics Announces Oversubscribed $160.0 Million Private Placement Financing

Mar 9, 2026, 7:05 AM EDT - 5 months ago

Relmada Therapeutics Announces Oversubscribed $160.0 Million Private Placement Financing

Relmada Therapeutics Reports 12-Month Phase 2 Interim Data for NDV-01 in Non-Muscle Invasive Bladder Cancer

Mar 9, 2026, 7:00 AM EDT - 5 months ago

Relmada Therapeutics Reports 12-Month Phase 2 Interim Data for NDV-01 in Non-Muscle Invasive Bladder Cancer

Relmada Therapeutics initiated with a Buy at Lucid Capital

2026-03-02T11:38:48.000Z - 6 months ago

Relmada Therapeutics initiated with a Buy at Lucid Capital

Relmada Therapeutics assumed at Outperform from Market Perform at Leerink

2026-01-23T11:25:12.000Z - 7 months ago

Relmada Therapeutics assumed at Outperform from Market Perform at Leerink

Relmada Therapeutics provides regulatory update on FDA alignment for NDV-01

2026-01-12T12:16:48.000Z - 7 months ago

Relmada Therapeutics provides regulatory update on FDA alignment for NDV-01

Relmada Therapeutics Provides Regulatory Update Confirming FDA Alignment on Registrational Studies Design for NDV-01 for Two Separate Indications

Jan 12, 2026, 7:00 AM EST - 7 months ago

Relmada Therapeutics Provides Regulatory Update Confirming FDA Alignment on Registrational Studies Design for NDV-01 for Two Separate Indications

Relmada Therapeutics initiated with a Buy at Jefferies

2025-12-22T00:10:11.000Z - 8 months ago

Relmada Therapeutics initiated with a Buy at Jefferies

Relmada Therapeutics to present NDV-01 Phase 2 data at SUO meeting

2025-12-03T12:35:52.000Z - 9 months ago

Relmada Therapeutics to present NDV-01 Phase 2 data at SUO meeting

Relmada Therapeutics Announces Presentation of NDV-01 Phase 2 Data at the Society for Urologic Oncology

Dec 3, 2025, 7:30 AM EST - 9 months ago

Relmada Therapeutics Announces Presentation of NDV-01 Phase 2 Data at the Society for Urologic Oncology

Mizuho upgrades Relmada to Outperform with ‘more upside’ ahead

2025-11-19T13:40:55.000Z - 9 months ago

Mizuho upgrades Relmada to Outperform with ‘more upside’ ahead

Relmada Therapeutics Slides: Investor presentation

Nov 14, 2025, 6:00 AM EST - 9 months ago

Relmada Therapeutics Slides: Investor presentation

Relmada Therapeutics Earnings Call Transcript: Q3 2025

Nov 13, 2025, 4:30 PM EST - 9 months ago

Relmada Therapeutics Earnings Call Transcript: Q3 2025

Relmada Therapeutics Earnings release: Q3 2025

Nov 13, 2025, 4:30 PM EST - 9 months ago

Relmada Therapeutics Earnings release: Q3 2025

Relmada Therapeutics Quarterly report: Q3 2025

Nov 13, 2025, 4:30 PM EST - 9 months ago

Relmada Therapeutics Quarterly report: Q3 2025

Relmada Therapeutics Reports Third Quarter 2025 Financial Results and Provides Key Clinical, Regulatory, and Corporate Updates

Nov 13, 2025, 4:01 PM EST - 9 months ago

Relmada Therapeutics Reports Third Quarter 2025 Financial Results and Provides Key Clinical, Regulatory, and Corporate Updates

Relmada Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 13, 2025

Nov 7, 2025, 7:30 AM EST - 10 months ago

Relmada Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 13, 2025

Relmada Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Nov 4, 2025, 7:09 AM EST - 10 months ago

Relmada Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Relmada Announces FDA Feedback Supporting 2 Separate Acceptable Registrational Study Paths for NDV-01 in Non-muscle Invasive Bladder Cancer

Nov 4, 2025, 7:01 AM EST - 10 months ago

Relmada Announces FDA Feedback Supporting 2 Separate Acceptable Registrational Study Paths for NDV-01 in Non-muscle Invasive Bladder Cancer

Relmada Therapeutics Appoints Distinguished Urologic Oncologist, Max Kates, MD, to the Clinical Advisory Board to Support Development of NDV-01

Oct 7, 2025, 7:30 AM EDT - 11 months ago

Relmada Therapeutics Appoints Distinguished Urologic Oncologist, Max Kates, MD, to the Clinical Advisory Board to Support Development of NDV-01

Relmada Therapeutics Transcript: Small-Cap Virtual Conference

Sep 18, 2025, 10:00 AM EDT - 11 months ago

Relmada Therapeutics Transcript: Small-Cap Virtual Conference

Relmada Regains Compliance with Nasdaq Minimum Bid Price Requirement

Sep 16, 2025, 9:00 AM EDT - 1 year ago

Relmada Regains Compliance with Nasdaq Minimum Bid Price Requirement

Relmada Issues Mid-Year CEO Letter to Shareholders

Sep 10, 2025, 7:15 AM EDT - 1 year ago

Relmada Issues Mid-Year CEO Letter to Shareholders

Relmada Therapeutics Earnings Call Transcript: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 1 year ago

Relmada Therapeutics Earnings Call Transcript: Q2 2025

Relmada Therapeutics Quarterly report: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 1 year ago

Relmada Therapeutics Quarterly report: Q2 2025

Relmada Therapeutics Earnings release: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 1 year ago

Relmada Therapeutics Earnings release: Q2 2025

Relmada Therapeutics Reports Second Quarter 2025 Financial Results and Announces NDV-01 6-Month Follow-up Safety and Efficacy Data in NMIBC

Aug 7, 2025, 4:05 PM EDT - 1 year ago

Relmada Therapeutics Reports Second Quarter 2025 Financial Results and Announces NDV-01 6-Month Follow-up Safety and Efficacy Data in NMIBC

Relmada Therapeutics to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025

Jul 31, 2025, 7:00 AM EDT - 1 year ago

Relmada Therapeutics to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025

Relmada Therapeutics Appoints Renowned Urologic Oncologist, Yair Lotan, MD, to Chair the Clinical Advisory Board and Support Development of NDV-01

Jul 15, 2025, 8:00 AM EDT - 1 year ago

Relmada Therapeutics Appoints Renowned Urologic Oncologist, Yair Lotan, MD, to Chair the Clinical Advisory Board and Support Development of NDV-01

DIMERx Appoints Biotech Leader Sergio Traversa, PharmD, to Board of Directors

Jul 9, 2025, 8:00 AM EDT - 1 year ago

DIMERx Appoints Biotech Leader Sergio Traversa, PharmD, to Board of Directors

Relmada Therapeutics Appoints Urology Expert Raj S. Pruthi, MD as CMO-Urology

Jun 17, 2025, 7:00 AM EDT - 1 year ago

Relmada Therapeutics Appoints Urology Expert Raj S. Pruthi, MD as CMO-Urology

Relmada Therapeutics Earnings Call Transcript: Q1 2025

May 12, 2025, 4:30 PM EDT - 1 year ago

Relmada Therapeutics Earnings Call Transcript: Q1 2025

Relmada Therapeutics Earnings release: Q1 2025

May 12, 2025, 4:30 PM EDT - 1 year ago

Relmada Therapeutics Earnings release: Q1 2025

Relmada Therapeutics Quarterly report: Q1 2025

May 12, 2025, 4:30 PM EDT - 1 year ago

Relmada Therapeutics Quarterly report: Q1 2025

Relmada Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 12, 2025, 4:01 PM EDT - 1 year ago

Relmada Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Relmada Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025

May 8, 2025, 7:30 AM EDT - 1 year ago

Relmada Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025

Relmada Therapeutics Transcript: Status Update

Apr 28, 2025, 4:30 PM EDT - 1 year ago

Relmada Therapeutics Transcript: Status Update

Relmada Therapeutics Press release: Status Update

Apr 28, 2025, 4:30 PM EDT - 1 year ago

Relmada Therapeutics Press release: Status Update

Relmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Data at AUA2025

Apr 28, 2025, 1:38 PM EDT - 1 year ago

Relmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Data at AUA2025

UPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025

Apr 27, 2025, 9:00 AM EDT - 1 year ago

UPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025

Relmada Therapeutics to Host KOL Event on Phase 2 NDV-01 Data

Apr 24, 2025, 8:00 AM EDT - 1 year ago

Relmada Therapeutics to Host KOL Event on Phase 2 NDV-01 Data

Relmada Therapeutics To Present NDV-01 Data at AUA2025

Apr 14, 2025, 7:30 AM EDT - 1 year ago

Relmada Therapeutics To Present NDV-01 Data at AUA2025

Relmada Therapeutics Proxy statement: Proxy Filing

Apr 11, 2025, 8:00 AM EDT - 1 year ago

Relmada Therapeutics Proxy statement: Proxy Filing

Relmada Therapeutics Proxy statement: Proxy Filing

Apr 11, 2025, 8:00 AM EDT - 1 year ago

Relmada Therapeutics Proxy statement: Proxy Filing

Relmada Therapeutics Earnings Call Transcript: Q4 2024

Mar 27, 2025, 4:30 PM EDT - 1 year ago

Relmada Therapeutics Earnings Call Transcript: Q4 2024

Relmada Therapeutics Annual report: Q4 2024

Mar 27, 2025, 4:30 PM EDT - 1 year ago

Relmada Therapeutics Annual report: Q4 2024

Relmada Therapeutics Earnings release: Q4 2024

Mar 27, 2025, 4:30 PM EDT - 1 year ago

Relmada Therapeutics Earnings release: Q4 2024

Relmada Therapeutics Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update

Mar 27, 2025, 4:05 PM EDT - 1 year ago

Relmada Therapeutics Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update

Relmada Therapeutics to Report Fourth Quarter 2024 Financial Results on Thursday, March 27, 2025

Mar 26, 2025, 9:00 AM EDT - 1 year ago

Relmada Therapeutics to Report Fourth Quarter 2024 Financial Results on Thursday, March 27, 2025

Relmada Therapeutics Licenses Phase 2 Bladder Cancer Candidate, NDV-01, from Trigone Pharma, Ltd.

Mar 25, 2025, 7:30 AM EDT - 1 year ago

Relmada Therapeutics Licenses Phase 2 Bladder Cancer Candidate, NDV-01, from Trigone Pharma, Ltd.

Relmada Therapeutics Acquires Potential Therapy for Tourette Syndrome from Asarina Pharma AB

Feb 6, 2025, 7:30 AM EST - 1 year ago

Relmada Therapeutics Acquires Potential Therapy for Tourette Syndrome from Asarina Pharma AB

Relmada discontinues late-stage trials for depression drug, explores sale

Dec 9, 2024, 8:11 AM EST - 1 year ago

Relmada discontinues late-stage trials for depression drug, explores sale

Relmada Therapeutics to Discontinue the Reliance II and Relight Phase 3 Studies of REL-1017

Dec 9, 2024, 7:30 AM EST - 1 year ago

Relmada Therapeutics to Discontinue the Reliance II and Relight Phase 3 Studies of REL-1017

Relmada's depression drug unlikely to meet main trial goal, analysis shows

Dec 4, 2024, 8:00 AM EST - 1 year ago

Relmada's depression drug unlikely to meet main trial goal, analysis shows

Relmada Therapeutics Reports That Data Monitoring Committee (DMC) Assessment Indicates That the Phase 3 Reliance II Trial is Futile at its Interim Analysis and is Unlikely to Meet the Primary Efficacy Endpoint with Statistical Significance

Dec 4, 2024, 7:30 AM EST - 1 year ago

Relmada Therapeutics Reports That Data Monitoring Committee (DMC) Assessment Indicates That the Phase 3 Reliance II Trial is Futile at its Interim Analysis and is Unlikely to Meet the Primary Efficacy Endpoint with Statistical Significance

Kuehn Law Encourages Investors of Relmada Therapeutics, Inc. to Contact Law Firm

Nov 21, 2024, 1:34 PM EST - 1 year ago

Kuehn Law Encourages Investors of Relmada Therapeutics, Inc. to Contact Law Firm

Relmada Therapeutics Transcript: Jefferies London Healthcare Conference

Nov 20, 2024, 7:00 AM EST - 1 year ago

Relmada Therapeutics Transcript: Jefferies London Healthcare Conference

Relmada Therapeutics Initiates Phase 1 Dosing with REL-P11 for Metabolic Disease

Nov 14, 2024, 7:30 AM EST - 1 year ago

Relmada Therapeutics Initiates Phase 1 Dosing with REL-P11 for Metabolic Disease

Relmada Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 7, 2024, 4:32 PM EST - 1 year ago

Relmada Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Relmada Therapeutics Earnings Call Transcript: Q3 2024

Nov 7, 2024, 4:30 PM EST - 1 year ago

Relmada Therapeutics Earnings Call Transcript: Q3 2024

Relmada Therapeutics Quarterly report: Q3 2024

Nov 7, 2024, 4:30 PM EST - 1 year ago

Relmada Therapeutics Quarterly report: Q3 2024

Relmada Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024

Nov 4, 2024, 4:30 PM EST - 1 year ago

Relmada Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024

Relmada Therapeutics Registration statement: Registration Filing

Aug 30, 2024, 8:00 AM EDT - 2 years ago

Relmada Therapeutics Registration statement: Registration Filing

Relmada Therapeutics Earnings Call Transcript: Q2 2024

Aug 7, 2024, 4:30 PM EDT - 2 years ago

Relmada Therapeutics Earnings Call Transcript: Q2 2024

Relmada Therapeutics Quarterly report: Q2 2024

Aug 7, 2024, 4:30 PM EDT - 2 years ago

Relmada Therapeutics Quarterly report: Q2 2024

Relmada Therapeutics Earnings release: Q2 2024

Aug 7, 2024, 4:30 PM EDT - 2 years ago

Relmada Therapeutics Earnings release: Q2 2024

Relmada Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 7, 2024, 4:05 PM EDT - 2 years ago

Relmada Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Relmada Therapeutics to Report Second Quarter 2024 Financial Results on August 7, 2024

Aug 5, 2024, 7:30 AM EDT - 2 years ago

Relmada Therapeutics to Report Second Quarter 2024 Financial Results on August 7, 2024

VolcanicTrades
VolcanicTrades Aug. 11 at 11:49 PM
$RLMD lot of bio stocks curling up….$BEAT $ONCO $GLMD
0 · Reply
teaman60
teaman60 Aug. 7 at 11:16 AM
$RLMD I was right
1 · Reply
StocktwitsEarnings
StocktwitsEarnings Aug. 6 at 10:04 PM
$RLMD Q2 '26 Earnings Results & Recap Reported GAAP EPS of -$0.11 up 63.33% YoY
0 · Reply
EarningsInsider
EarningsInsider Aug. 6 at 9:22 PM
https://www.marketbeat.com/earnings/reports/2026-8-6-relmada-therapeutics-inc-stock/ $RLMD Relmada Therapeutics Earnings Transcript
0 · Reply
teaman60
teaman60 Aug. 5 at 1:59 AM
$RLMD Well we have passed the time when they said test results would be released so I am not expecting good news on this.
1 · Reply
Lane0507
Lane0507 Aug. 4 at 10:49 PM
$RLMD A sleeper ready to bounce
0 · Reply
Quantumup
Quantumup Jul. 31 at 12:21 PM
$NBIX Baird-OP⬆️$225 was$186 Stifel-Buy⬆️$215 was$188 SLNO $RYTM $RLMD HRMY Needham-Buy⬆️$204 was$200~continue2see meaningful NBIX upside—driven by an established Ingrezza franchise—2 add'l growth products—well funded pipeline—w/ multiple data readouts '27+ Guggenheim-Buy⬆️$222 was $200; Here's what Guggenheim had to say in its note to investors: https://x.com/Quantumup1/status/2083165891739390434?s=20
0 · Reply
focafoca99
focafoca99 Jul. 28 at 12:47 PM
$RLMD installed Bipin Dalmia, PhD, MBA as its new chief business officer.
1 · Reply
PLATINUM_TRADES
PLATINUM_TRADES Jul. 22 at 1:52 PM
$RLMD $5.11 Is the 200 major support I expect a bounce 🚨🚨
1 · Reply
PLATINUM_TRADES
PLATINUM_TRADES Jul. 22 at 1:40 PM
$RLMD Adds!! No reason for this to be this low imo... $5.50 Possible next🔋🔋
0 · Reply
VikaDelic
VikaDelic Jul. 21 at 2:44 PM
$RLMD bottom is close, adding some back
0 · Reply
metalcook
metalcook Jul. 21 at 11:36 AM
$RLMD any catalysts coming up or desert storm?
0 · Reply
SannieVerraderlijk
SannieVerraderlijk Jul. 16 at 4:41 PM
$RLMD Added here
1 · Reply
Doozio
Doozio Jun. 27 at 3:25 PM
$RLMD it’s only obvious wen it’s obvious ENTA 🐒🍌🧠⏰♾️
0 · Reply
Doozio
Doozio Jun. 27 at 3:24 PM
$RLMD da 🐑 are SKWD again as da rotation ONTA semis ENTA biotechs out of the tightness 🐒🍌🧠⏰♾️
0 · Reply
SannieVerraderlijk
SannieVerraderlijk Jun. 19 at 5:58 AM
$ABOS $CCCC $NKTR $RLMD $ SABS $ ZURA Some longs added to Russell 3000 yesterday
0 · Reply
Eathapoo
Eathapoo Jun. 16 at 5:05 PM
$VTGN hoping for the best here. I made the mistake selling $RLMD for $0.60 and then 💥. Holding strong. Let go $5.
0 · Reply
PLATINUM_TRADES
PLATINUM_TRADES Jun. 10 at 1:48 PM
$RLMD $6.56 Broke.. $6.80 Next major resistance... Who loves June 🥇🥇
0 · Reply
PLATINUM_TRADES
PLATINUM_TRADES Jun. 10 at 1:39 PM
$RLMD Another overnight swing winner 🥇🥇. $6.56 Still possible imo🚨🚨
0 · Reply
PLATINUM_TRADES
PLATINUM_TRADES Jun. 10 at 11:46 AM
$RLMD $RLMD adds! $6.56 Next major resistance 🚨 🚨
0 · Reply
teaman60
teaman60 Jun. 2 at 4:53 PM
$RLMD Looks like maybe some bad test results have leaked
2 · Reply